이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

argenx 배당금

배당금 기준 확인 0/6

argenx 배당금을 지급한 기록이 없습니다.

주요 정보

n/a

배당 수익률

n/a

지급 비율

업계 평균 수익률	1.8%
다음 배당금 지급일	n/a
전 배당일	n/a
주당 배당금	n/a
주당 순이익	-€5.52
3년 후 배당 수익률 예측	0%

최근 배당금 업데이트

업데이트 없음

Recent updates

Analyst Estimates: Here's What Brokers Think Of argenx SE (EBR:ARGX) After Its Yearly Report

Mar 24

Analysts Have Made A Financial Statement On argenx SE's (EBR:ARGX) Full-Year Report

Mar 05

argenx SE (EBR:ARGX) Shares Could Be 24% Below Their Intrinsic Value Estimate

Feb 23

Getting In Cheap On argenx SE (EBR:ARGX) Is Unlikely

Dec 18

Broker Revenue Forecasts For argenx SE (EBR:ARGX) Are Surging Higher

Jul 28

An Intrinsic Calculation For argenx SE (EBR:ARGX) Suggests It's 31% Undervalued

Jul 17

Revenues Tell The Story For argenx SE (EBR:ARGX)

Jun 20

argenx (EBR:ARGX) Is Using Debt Safely

May 08

We Think argenx (EBR:ARGX) Can Afford To Drive Business Growth

Apr 20

Does argenx (EBR:ARGX) Have A Healthy Balance Sheet?

Dec 27

We're Not Very Worried About argenx's (EBR:ARGX) Cash Burn Rate

Oct 08

결제의 안정성과 성장

배당금 데이터 가져오기

안정적인 배당: 과거에 ARGX 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.

배당금 증가: ARGX 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.

시장 대비 배당 수익률

argenx 시장 대비 배당 수익률

ARGX 배당 수익률은 시장과 어떻게 비교되나요?
세그먼트	배당 수익률
회사 (ARGX)	n/a
시장 하위 25% (BE)	2.2%
시장 상위 25% (BE)	7.4%
업계 평균 (Biotechs)	1.8%
3년 후 애널리스트 예측 (ARGX)	0%

주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 ARGX 의 배당 수익률을 평가할 수 없습니다.

고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 ARGX 의 배당 수익률을 평가할 수 없습니다.

주주에 대한 수익 배당금

수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 ARGX 의 지급 비율을 계산하기에는 데이터가 부족합니다.

주주에 대한 현금 배당금

현금 흐름 범위: ARGX 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.

argenx 배당금

배당금 기준 확인 0/6

주요 정보

최근 배당금 업데이트

Recent updates

argenx SE's (EBR:ARGX) Shares Climb 26% But Its Business Is Yet to Catch Up

argenx SE Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy

Consensus EPS estimates fall by 12%, revenue upgraded

First quarter 2024 earnings released: US$1.04 loss per share (vs US$0.52 loss in 1Q 2023)

argenx SE Appoints Dr. Brian L. Kotzin as Non-Executive Director to the Board of Directors

argenx SE's (EBR:ARGX) CEO Looks Like They Deserve Their Pay Packet

argenx SE Announces Data from its Phase 3 ADHERE Trial Evaluating VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy

Investors Appear Satisfied With argenx SE's (EBR:ARGX) Prospects

argenx Se Advances Clinical Development of Efgartigimod in Primary Sjogren's Disease

Argenx SE Announces Approval of Vyvgart (Efgartigimod Alfa) in Japan for Adults with Primary Immune Thrombocytopenia

Analyst Estimates: Here's What Brokers Think Of argenx SE (EBR:ARGX) After Its Yearly Report

Consensus EPS estimates upgraded to US$1.43 loss

Consensus estimates of losses per share improve by 13%

Analysts Have Made A Financial Statement On argenx SE's (EBR:ARGX) Full-Year Report

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

argenx SE (EBR:ARGX) Shares Could Be 24% Below Their Intrinsic Value Estimate

argenx SE Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy

argenx SE Announces Approval of VYVDURA (efgartigimod Alfa and Hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia Gravis

argenx SE, Annual General Meeting, May 07, 2024

CEO & Executive Director recently sold €1.0m worth of stock

Price target decreased by 11% to €459

argenx SE Reports Topline Results from ADDRESS Study of Efgartigimod SC in Pemphigus

Getting In Cheap On argenx SE (EBR:ARGX) Is Unlikely

Forecast to breakeven in 2025

Forecast to breakeven in 2025

Consensus EPS estimates upgraded to US$4.76 loss, revenue downgraded

argenx SE Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune Thrombocytopenia

Consensus EPS estimates fall by 17%

argenx SE Announces European Commission Approval of Subcutaneous VYVGART (efgartigimod alfa) for Generalized Myasthenia Gravis

Argenx Se Announces 20 Presentations of Clinical Trial and Real-World Data from Studies of Vyvgart® and Vyvgart Hytrulo® (Vyvgart) in Neuromuscular Autoimmune Disease

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus estimates of losses per share improve by 16%

Consensus EPS estimates fall by 19%

Independent Chairman of the Board recently sold €3.8m worth of stock

Argenx Announces VYVGART (Efgartigimod Alfa) Authorized for Sale by Health Canada for Generalized Myasthenia Gravis

CEO & Executive Director exercised options to buy €36m worth of stock.

CEO & Executive Director recently sold €1.9m worth of stock

Independent Non-Executive Director exercised options and sold €3.3m worth of stock

Consensus EPS estimates upgraded to US$4.71 loss

Consensus revenue estimates increase by 10%

Price target increased by 8.0% to €491

Broker Revenue Forecasts For argenx SE (EBR:ARGX) Are Surging Higher

argenx SE to Report Fiscal Year 2023 Results on Feb 29, 2024

New minor risk - Shareholder dilution

Price target increased by 9.4% to €476

New major risk - Share price stability

Consensus EPS estimates upgraded to US$5.73 loss

Zai Lab and argenx Report Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy

Forecast to breakeven in 2025

Zai Lab and argenx Report Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy

An Intrinsic Calculation For argenx SE (EBR:ARGX) Suggests It's 31% Undervalued

Zai Lab Limited and argenx Announce Approval of VYVGART (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China

argenx SE Announces U.S. Food and Drug Administration Approval of VYVGART Hytrulo Injection for Subcutaneous Use in Generalized Myasthenia Gravis

Revenues Tell The Story For argenx SE (EBR:ARGX)

Now 20% undervalued

Consensus EPS estimates upgraded to US$6.53 loss

Now 21% undervalued

Consensus estimates of losses per share improve by 13%

argenx (EBR:ARGX) Is Using Debt Safely

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Forecast to breakeven in 2025

We Think argenx (EBR:ARGX) Can Afford To Drive Business Growth

CEO & Executive Director recently sold €118k worth of stock

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Consensus estimates of losses per share improve by 23%

argenx SE Receives Notification of PDUFA Date Extension for SC Efgartigimod

argenx SE Announces Werner Lanthaler Will Resign as Non-Executive Director of Board and Chair of Audit and Compliance Committee

Forecast to breakeven in 2025

Does argenx (EBR:ARGX) Have A Healthy Balance Sheet?

argenx SE Appoints Ana Cespedes as Non-Executive Director to Its Board of Directors

argenx SE Announces U.S. FDA Acceptance of Biologics License Application for Subcutaneous Efgartigimod in Generalized Myasthenia Gravis with Priority Review

Consensus forecasts updated

Insufficient new directors

Independent Non-Executive Director recently sold €960k worth of stock

argenx SE Announces the Retirement of Hans De Haard as Chief Scientific Officer